Show simple item record

dc.contributor.authorQuattrone, Diego
dc.contributor.authorFerraro, Laura
dc.contributor.authorTripoli, Giada
dc.contributor.authorLa Cascia, Caterina
dc.contributor.authorQuigley, Harriet
dc.contributor.authorQuattrone, Andrea
dc.contributor.authorJongsma, Hannah E
dc.contributor.authorDel Peschio, Simona
dc.contributor.authorGatto, Giusy
dc.contributor.authorEU-GEI group
dc.contributor.authorGayer-Anderson, Charlotte
dc.contributor.authorJones, Peter B
dc.contributor.authorKirkbride, James B
dc.contributor.authorLa Barbera, Daniele
dc.contributor.authorTarricone, Ilaria
dc.contributor.authorBerardi, Domenico
dc.contributor.authorTosato, Sarah
dc.contributor.authorLasalvia, Antonio
dc.contributor.authorSzöke, Andrei
dc.contributor.authorArango, Celso
dc.contributor.authorBernardo, Miquel
dc.contributor.authorBobes, Julio
dc.contributor.authorDel Ben, Cristina Marta
dc.contributor.authorMenezes, Paulo Rossi
dc.contributor.authorLlorca, Pierre-Michel
dc.contributor.authorSantos, Jose Luis
dc.contributor.authorSanjuán, Julio
dc.contributor.authorTortelli, Andrea
dc.contributor.authorVelthorst, Eva
dc.contributor.authorde Haan, Lieuwe
dc.contributor.authorRutten, Bart PF
dc.contributor.authorLynskey, Michael T
dc.contributor.authorFreeman, Tom P
dc.contributor.authorSham, Pak C
dc.contributor.authorCardno, Alastair G
dc.contributor.authorVassos, Evangelos
dc.contributor.authorvan Os, Jim
dc.contributor.authorMorgan, Craig
dc.contributor.authorReininghaus, Ulrich
dc.contributor.authorLewis, Cathryn M
dc.contributor.authorMurray, Robin M
dc.contributor.authorDi Forti, Marta
dc.date.accessioned2020-01-17T00:30:39Z
dc.date.available2020-01-17T00:30:39Z
dc.date.issued2020-03-18
dc.identifier.issn0033-2917
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/300961
dc.description.abstractBACKGROUND: Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first-episode psychosis (FEP) patients. METHOD: We analysed data from 901 FEP patients and 1235 controls recruited across six countries, as part of the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We used item response modelling to estimate two bifactor models, which included general and specific dimensions of psychotic symptoms in patients and psychotic experiences in controls. The associations between these dimensions and cannabis use were evaluated using linear mixed-effects models analyses. RESULTS: In patients, there was a linear relationship between the positive symptom dimension and the extent of lifetime exposure to cannabis, with daily users of high-potency cannabis having the highest score (B = 0.35; 95% CI 0.14-0.56). Moreover, negative symptoms were more common among patients who never used cannabis compared with those with any pattern of use (B = -0.22; 95% CI -0.37 to -0.07). In controls, psychotic experiences were associated with current use of cannabis but not with the extent of lifetime use. Neither patients nor controls presented differences in depressive dimension related to cannabis use. CONCLUSIONS: Our findings provide the first large-scale evidence that FEP patients with a history of daily use of high-potency cannabis present with more positive and less negative symptoms, compared with those who never used cannabis or used low-potency types.
dc.description.sponsorshipThe work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust to DQ; DFG Heisenberg professorship (no. 389624707) to UR. National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherCambridge University Press (CUP)
dc.rightsAll rights reserved
dc.subjectEU-GEI group
dc.titleDaily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
dc.typeArticle
prism.endingPage9
prism.publicationDate2020
prism.publicationNamePsychol Med
prism.startingPage1
dc.identifier.doi10.17863/CAM.48036
dcterms.dateAccepted2020-01-08
rioxxterms.versionofrecord10.1017/S0033291720000082
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2020-03-18
dc.contributor.orcidQuattrone, Diego [0000-0002-6051-8309]
dc.identifier.eissn1469-8978
rioxxterms.typeJournal Article/Review
cam.issuedOnline2020-03-18
cam.orpheus.successTue Mar 31 10:37:35 BST 2020 - Embargo updated
cam.orpheus.counter2
rioxxterms.freetoread.startdate2020-09-18


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record